Immune Checkpoint Inhibitor-related Hypogonadism and Infertility: a Neglected Issue in Immuno-oncology

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2021 Feb 16

PMID 33589529

Citations 19

Authors

Berna C Ozdemir

Affiliations

Soon will be listed here.

Abstract

Despite a significant amount of data on incidence and therapy of immune-related adverse events affecting virtually all organ systems, the potential impact of immune checkpoint inhibitors (ICIs) on gonadal function has not been sufficiently studied. The limited evidence available suggests that ICI-related primary hypogonadism due to orchitis as well as secondary hypogonadism due to hypophysitis are a potential risk for infertility. A systematic investigation of gonadal function under ICIs is warranted given the increasing application of ICIs in the adjuvant setting, among young adults and children and the possible influence of sex hormone levels on the efficacy and toxicity of ICIs.

Citing Articles

The potential role of exercise in mitigating fertility toxicity associated with immune checkpoint inhibitors (ICIs) in cancer patients.

Jamrasi P, Tazi M, Zulkifli N, Bae J, Song W J Physiol Sci. 2024; 74(1):57.

PMID: 39616333 PMC: 11607910. DOI: 10.1186/s12576-024-00950-3.

Case report: A case of sintilimab-induced recurrent diabetic ketoacidosis and thyroid dysfunction in a patient with advanced cervical carcinoma.

Wang C, Cai Y, Feng P Front Immunol. 2024; 15:1405856.

PMID: 39450164 PMC: 11499202. DOI: 10.3389/fimmu.2024.1405856.

Aberrant CD8T cells drive reproductive dysfunction in female mice with elevated IFN-γ levels.

Bafor E, Erwin-Cohen R, Martin T, Baker C, Kimmel A, Duverger O Front Immunol. 2024; 15:1368572.

PMID: 38698852 PMC: 11064017. DOI: 10.3389/fimmu.2024.1368572.

Fertility Preservation in the Era of Immuno-Oncology: Lights and Shadows.

Silvestris E, DOronzo S, Petracca E, DAddario C, Cormio G, Loizzi V J Pers Med. 2024; 14(4).

PMID: 38673058 PMC: 11050999. DOI: 10.3390/jpm14040431.

Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?.

Ntemou E, Delgouffe E, Goossens E Cancers (Basel). 2024; 16(6).

PMID: 38539511 PMC: 10968841. DOI: 10.3390/cancers16061176.

References

Scovell J, Benz K, Samarska I, Kohn T, Hooper J, Matoso A . Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma. JAMA Oncol. 2020; 6(8):1297-1299. PMC: 7303895. DOI: 10.1001/jamaoncol.2020.1641. View

Albarel F, Gaudy C, Castinetti F, Carre T, Morange I, Conte-Devolx B . Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2014; 172(2):195-204. DOI: 10.1530/EJE-14-0845. View

Andersson T, Johansson A, Fredriksson I, Lambe M . Cancer during pregnancy and the postpartum period: A population-based study. Cancer. 2015; 121(12):2072-7. DOI: 10.1002/cncr.29325. View

Garon-Czmil J, Petitpain N, Rouby F, Sassier M, Babai S, Yelehe-Okouma M . Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database. Sci Rep. 2019; 9(1):19419. PMC: 6923385. DOI: 10.1038/s41598-019-56026-5. View

Haslam A, Prasad V . Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019; 2(5):e192535. PMC: 6503493. DOI: 10.1001/jamanetworkopen.2019.2535. View

Nogueira E, Newsom-Davis T, Morganstein D . Immunotherapy-induced endocrinopathies: assessment, management and monitoring. Ther Adv Endocrinol Metab. 2020; 10:2042018819896182. PMC: 6933543. DOI: 10.1177/2042018819896182. View

Xu W, Moor R, Walpole E, Atkinson V . Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Res. 2019; 29(3):333-337. DOI: 10.1097/CMR.0000000000000586. View

Poulet F, Wolf J, Herzyk D, DeGeorge J . An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors. Birth Defects Res B Dev Reprod Toxicol. 2016; 107(2):108-19. DOI: 10.1002/bdrb.21176. View

Ryder M, Callahan M, Postow M, Wolchok J, Fagin J . Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014; 21(2):371-81. PMC: 4573438. DOI: 10.1530/ERC-13-0499. View

10.

Ozdemir B, Dotto G . Sex Hormones and Anticancer Immunity. Clin Cancer Res. 2019; 25(15):4603-4610. DOI: 10.1158/1078-0432.CCR-19-0137. View

11.

Brunet-Possenti F, Opsomer M, Gomez L, Ouzaid I, Descamps V . Immune checkpoint inhibitors-related orchitis. Ann Oncol. 2017; 28(4):906-907. DOI: 10.1093/annonc/mdw696. View

12.

Mehta A, Kim K, Minor D . Case Report of a Pregnancy During Ipilimumab Therapy. J Glob Oncol. 2018; 4:1-3. PMC: 6180753. DOI: 10.1200/JGO.17.00019. View

13.

Faje A, Sullivan R, Lawrence D, Tritos N, Fadden R, Klibanski A . Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014; 99(11):4078-85. DOI: 10.1210/jc.2014-2306. View

14.

Martins F, Sofiya L, Sykiotis G, Lamine F, Maillard M, Fraga M . Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019; 16(9):563-580. DOI: 10.1038/s41571-019-0218-0. View

15.

Quach H, Robbins C, Balko J, Chiu C, Miller S, Wilson M . Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy. Oncologist. 2019; 24(7):872-876. PMC: 6656444. DOI: 10.1634/theoncologist.2018-0722. View

16.

Burotto M, Gormaz J, Samtani S, Valls N, Silva R, Rojas C . Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. Semin Oncol. 2018; 45(3):164-169. DOI: 10.1053/j.seminoncol.2018.03.003. View

17.

Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G . Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. Lancet Oncol. 2018; 19(6):737-746. DOI: 10.1016/S1470-2045(18)30261-4. View

18.

Bucheit A, Hardy J, Szender J, Glitza Oliva I . Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition. Melanoma Res. 2020; 30(4):423-425. DOI: 10.1097/CMR.0000000000000657. View

19.

Miller K, Fidler-Benaoudia M, Keegan T, Hipp H, Jemal A, Siegel R . Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020; 70(6):443-459. DOI: 10.3322/caac.21637. View

20.

Bai X, Lin X, Zheng K, Chen X, Wu X, Huang Y . Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Endocrine. 2020; 69(3):670-681. PMC: 7447663. DOI: 10.1007/s12020-020-02355-9. View